<!DOCTYPE html>
<html>
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <link rel="stylesheet" type="text/css" href="css/style-manual.css">
    <link rel="stylesheet" href="https://www.w3schools.com/w3css/4/w3.css">
    <script src="js/script.js"></script>
</head>
<body>
<!--Diplin-------------------------------------------------------->
<div class="bodyDiv" id="idDiplin">
    <div class="w3-container w3-center w3-animate-left">
        <h2 class="mango">Diplin</h2>
    </div>
<strong>Product Orientation & Presentation:</strong>
<table class="table1">
<tr>
<th>Brand Name:
</th>
<th>Diplin 5 & Diplin M
</th>
</tr>
<tr>
<td>Generic & Strength:
</td>
<td>Linagliptin 5 mg.
<br>
Linagliptin 2.5 mg & Metformin HCl 500 mg.
</td>
</tr>
<tr>
<td>Dosage Form:
</td>
<td>Tablet.
</td>
</tr>
<tr>
<td>Therapeutic Class:
</td>
<td>Antidiabetic/ Hypoglycemic.
</td>
</tr>
</tr>
<tr>
<td>Sub Therapeutic class: 
</td>
<td>Dipeptidyl Peptidase-4 (DPP-4) inhibitor.
</td>
</tr>
<tr>
<td>Commercial Pack & Accessories:
</td>
<td>30's.(Diplin)
</td>
</tr>
<tr>
<td>Price (TP):
</td>
<td>15tk./ Tablet.(Diplin).
</td>
</tr>	
<tr>
<td>Flavour 
</td>
<td>---
</td>
</tr>
<tr>
<td>Indication: 
</td>
<td>&#x2022;   Type 2 Diabetes Mellitus.
</td>
</tr>
<tr>
<td>Pregnancy: 
</td>
<td>Pregnancy Category-B
</td>
</tr>
<tr>
<td>Lactation: 
</td>
<td>
If clearly needed.
</td>
</tr>
<tr>
<td>Children: 
</td>
<td>Safety and efficacy not established.
</td>
</tr>
<tr>
<td>Brand Name Justification: 
</td>
<td> <strong>Lin</strong>agliptin is a <strong>DP</strong>P-4 <strong>i</strong>nhibitor=Diplin.  
</td>
</tr>
<tr>
<td>Brand Slogan: 
</td>
<td>Diplin 5: Meets the challenge of control & care in diabetes management<br>
Diplin M: Effective combination to control blood sugar level.
</td>
</tr>
<tr>
<td colspan="4">
---
</td>
</tr>
</table>
<br>

<div class="a">
<strong>key selling points(KSP)(Diplin M):</strong><br>
<span>&#x261E;</span> Ensures effective glycemic control.<br>
<span>&#x261E;</span> Significantly improves FPG.<br>
<span>&#x261E;</span> More effective than Linagliptin alone.
</div>
<br>
<img src="img/Diplin-1.png" alt="" class="responsive-IMG" width="375" height="300">
<br>
<br>
<div class="a">
<strong>Diabetes?:</strong><br>
Diabetes is a group of metabolic disorder in which
persistent hyperglycaemia is caused by-<br>
<span>&#x261E;</span> Deficient insulin secretion or<br>
<span>&#x261E;</span> Resistance to the action of insulin
</div>
<br>
<br>

<div class="a">
<strong>Common symptoms of Diabetes:</strong><br>
<span>&#x261E;</span> Frequent urination.<br>
<span>&#x261E;</span> Unintended weight loss.<br>
<span>&#x261E;</span> Increased thirst & hunger.<br>
<span>&#x261E;</span> Fatigue.
</div>
<br>
<br>
<img src="img/Diplin-3.png" alt="" class="responsive-IMG" width="375" height="300">
<br>
<br>
<div class="a">
<strong>Diabetes is Manageable, But is not Curable</strong><br>
To maintain optimum blood glucose level, Diabetic patients needs:<br>
<span>&#x261E;</span> Diet+ Discipline+ Drug(3D Theory)
</div>
<br><br>

<div class="a">
<strong>Major Drugs Used to Control Diabetes:</strong><br>
<b>Oral hypoglycemic drug:</b><br>
<span>&#x261E;</span> <strong>Sulfonylurea:</strong> Glibenclamide, Glipizide, Gliclazide, Glimepiride.<br>

<span>&#x261E;</span> <strong>DPP-4 Inhibitors:</strong> Linagliptin, Sitagliptin, Vildagliptin, Saxagliptin.</strong><br>

<span>&#x261E;</span> <strong>Others Drugs:</strong> Metformin, Empagliflozin, Dapagliflozin, Canagliflozin, Pioglitazone, Voglibose, Repaglinide etc.
</div>
<br>
<br>
<strong>Advantages of DPP-4 inhibitors:</strong><br>
<span>&#x261E;</span> Low risk of hypoglycemia.<br>
<span>&#x261E;</span> Neutral effect on body weight.<br>
<span>&#x261E;</span> Well tolerated.<br>
<span>&#x261E;</span> Once-daily dosing.<br>
<span>&#x261E;</span> Increase Incretin action.<br>
<span>&#x261E;</span> Suitable for diabetic patients with CKD.<br>
<span>&#x261E;</span> Cardiac friendly profile.
</div>
<br><br>


<img src="img/Diplin-10.png" alt="" class="responsive-IMG" width="375" height="300">
<br>
<br>

<img src="img/Diplin-7.jpg" alt="" class="responsive-IMG" width="375" height="300">
<br>
<br>

<img src="img/Diplin-11.png" alt="" class="responsive-IMG" width="375" height="300">
<br>
<br>
<img src="img/Diplin-12.png" alt="" class="responsive-IMG" width="375" height="300">
<br>
<br>

<img src="img/Diplin-13.png" alt="" class="responsive-IMG" width="375" height="300">
<br>
<br>

<img src="img/Diplin-14.png" alt="" class="responsive-IMG" width="375" height="300">
<br>
<br>

<img src="img/Diplin-15.png" alt="" class="responsive-IMG" width="375" height="300">
<br>
<br>

<div class="a">
<strong>key selling points(KSP)(Diplin 5):</strong><br>
<span>&#x261E;</span> Ensures effective glycemic control.<br>
<span>&#x261E;</span> Effectively improves poorly controlled diabetes.<br>
<span>&#x261E;</span> Provides dosing simplicity.<br>
<span>&#x261E;</span> Ensures correct therapeutic dose always in patients having renal or hepatic impairment
Improves patient compliance.<br>
<span>&#x261E;</span> Safe for diabetic patients with cardiovascular problems.<br><br>
<span>&#x261E;</span> Ensures selectivity, potency & long action.<br>
<span>&#x261E;</span> Ensures more patients compliance.
</div>
<br>

<img src="img/Diplin-17.png" alt="" class="responsive-IMG" width="375" height="300">
<br>
<br>
<img src="img/Diplin-18.png" alt="" class="responsive-IMG" width="375" height="300">
<br>
<br>
<video width="320" height="240" controls>
<source src="Video/Diplin-1.mp4" type="video/mp4">
</video><br><br>
</div>   
<footer>
    <p>Â© 2024 Md. Nurullah. All rights reserved.</p>
</footer>
<center><div class="ovalEnd">The End-Diplin</div></center><!--End Line----> 
</body>
</html>